SCHEMBL15020945

SCHEMBL15020945

CCCCCCC(CCCC)C(=O)Nc1cc(C(=O)O)cc(C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
LMNA P02545 2/20 0.50
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HDAC8 Q9BY41 5/20 0.48
HDAC3 O15379 3/20 0.48
HDAC6 Q9UBN7 3/20 0.48
HDAC1 Q13547 3/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
CA2 P00918 2/20 0.44
CA1 P00915 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1525323 0.99 MEN1 (0.63) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL1525705 0.96 MEN1 (0.68) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL15021080 0.86 LMNA (0.68) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL1820404 0.86 LMNA (0.48) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL8616893 0.86 MEN1 (0.50) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL1525510 0.84 LMNA (0.69) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL10627759 0.84 HDAC1 (0.57) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL12050585 0.83 MEN1 (0.51) MEN1KMT2ALMNAALDH1A1HDAC8
SCHEMBL8616897 0.83 MEN1 (0.50) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL1525416 0.82 LMNA (0.65) MEN1KMT2ALMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9623345-B2 Phase selective gelation with alkylated aromatic acid compounds XEROX CORPORATION (US) 2017-04-18 US disclosed
US-9623345-B2 Phase selective gelation with alkylated aromatic acid compounds XEROX CORPORATION (US) 2017-04-18 US disclosed
US-9067878-B2 Organogel compositions comprising alkylated aromatic acids XEROX CORPORATION (US) 2015-06-30 US disclosed
US-20130158135-A1 Organogel Compositions Comprising Alkylated Aromatic Acids NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2013-06-20 US disclosed
US-20130153508-A1 Phase Selective Gelation With Alkylated Aromatic Acid Compounds NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158135-A1 Organogel Compositions Comprising Alkylated Aromatic Acids F12, AHR, RXRG MEN1 3557/4885KMT2A 2571/4885LMNA 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.